PUR1900

October 6, 2017October 6, 2017

FDA Opens the Door for People with Asthma to Use Antifungal Therapy Pulmazole

The U.S. Food and Drug Administration has agreed to Pulmatrix’s request to consider making the lung-fungus therapy Pulmazole (PUR1900) available to people with asthma in addition to people with allergic bronchopulmonary aspergillosis, or ... Read more

August 22, 2016August 22, 2016

FDA Grants Orphan Drug Status to Pulmatrix’s PUR1900 for Cystic Fibrosis Fungal Lung Infections

Cystic Fibrosis, News

The U.S. Food & Drug Administration (FDA) has granted orphan drug designation to Pulmatrix‘s PUR1900, an inhaled drug for the treatment of pulmonary fungal infections in patients with cystic fibrosis (CF). ... Read more

April 21, 2016April 21, 2016

Advances in Inhaled Drug Delivery for Lung Diseases Are Highlighted by Pulmatrix CSO

Cystic Fibrosis, News

With the growing problems caused by antimicrobial resistance, there is increased interest in the use of better strategies for drug delivery. David L. Hava, Ph.D., the chief scientific officer for Pulmatrix — a ... Read more

February 23, 2016May 13, 2016

Capsugel and Pulmatrix Partnering to Develop Inhaled Therapeutics for Range of Lung Diseases

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

Capsugel and Pulmatrix, Inc., entered a partnership to advance the development and manufacture of inhaled therapeutics to treat serious pulmonary diseases, based on Pulmatrix’s iSPERSE technology. “This collaboration provides us with ... Read more

September 14, 2015November 5, 2015

Pulmatrix To Present Promising Inhaled CF Therapy PUR1900 at Cystic Fibrosis Conference

Cystic Fibrosis, News

Pulmatrix, a biotechnology company developing new inhaled therapies to address pulmonary diseases through the company’s own clinically validated technology iSPERSE, recently announced that their lead investigational therapy for CF will ... Read more